Alnylam Pharmaceuticals' (ALNY) "Buy" Rating Reaffirmed at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY - Free Report) in a report issued on Friday morning,Benzinga reports. Chardan Capital currently has a $300.00 target price on the biopharmaceutical company's stock.

ALNY has been the topic of several other research reports. Morgan Stanley upped their price target on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Canaccord Genuity Group boosted their price target on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a "buy" rating in a research note on Tuesday, February 18th. Sanford C. Bernstein cut their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. Scotiabank decreased their price objective on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a "sector outperform" rating on the stock in a report on Friday, February 14th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $310.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, February 26th. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty have issued a buy rating to the company's stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $312.30.

Remove Ads

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY traded up $9.33 during midday trading on Friday, reaching $292.67. 1,073,493 shares of the company traded hands, compared to its average volume of 803,333. The firm's fifty day moving average price is $257.16 and its two-hundred day moving average price is $259.74. The firm has a market capitalization of $37.89 billion, a price-to-earnings ratio of -134.87 and a beta of 0.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Activity

In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 11,250 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CMO Pushkal Garg sold 52,592 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company's stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Larson Financial Group LLC grew its holdings in Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 73 shares during the period. Park Square Financial Group LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $28,000. R Squared Ltd purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $33,000. OFI Invest Asset Management bought a new position in Alnylam Pharmaceuticals during the 4th quarter valued at approximately $35,000. Finally, Colonial Trust Co SC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter valued at $35,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.